Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tabernero

Showing results (101-110 of 1,741) with videos related to

Pageof 175
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 3, 2022
The Evolving Treatment Landscape in <i>BRAF-V600E</i>-Mutated Metastatic Colorectal CancerJosep Tabernero, Javier Ros, Elena Élez
Vision Research|February 8, 2011
Neuronal adaptation to simulated and optically-induced astigmatic defocusArne Ohlendorf, Juan Tabernero, Frank Schaeffel
Anales Espanoles De Pediatria|January 1, 1992
[Development of renal scars in 25 children one year following an acute episode of pyelonephritis]M Tabernero Carrascosa, L Espinosa Román
The New England Journal of Medicine|February 27, 2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. ReplyScott Kopetz, Axel Grothey, Josep Tabernero
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 15, 2012
Depicting the evolving scenario of translational-guided drug developmentG Argilés, J Rodon, J Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Cell Cycle (Georgetown, Tex.)|December 9, 2014
Multi-target angiokinase inhibitors to fight resistanceOriol Casanovas, Ramon Salazar, Josep Tabernero
Current Treatment Options in Oncology|September 17, 2015
First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405Elena Elez, Guillem Argilés, Josep Tabernero
European Journal of Investigation in Health, Psychology and Education|September 20, 2021
Development and Validation of the Social Network Addiction Scale (SNAddS-6S)Esther Cuadrado, Rocío Rojas, Carmen Tabernero
Future Oncology (London, England)|November 13, 2025
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line <i>BRAF</i> V600E-mutant metastatic colorectal cancerScott Kopetz, Josep Tabernero, Elena Élez
Pageof 175

Showing results (101-110 of 1,741) with videos related to

Sort By:
Pageof 175
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 3, 2022
The Evolving Treatment Landscape in <i>BRAF-V600E</i>-Mutated Metastatic Colorectal CancerJosep Tabernero, Javier Ros, Elena Élez
Vision Research|February 8, 2011
Neuronal adaptation to simulated and optically-induced astigmatic defocusArne Ohlendorf, Juan Tabernero, Frank Schaeffel
Anales Espanoles De Pediatria|January 1, 1992
[Development of renal scars in 25 children one year following an acute episode of pyelonephritis]M Tabernero Carrascosa, L Espinosa Román
The New England Journal of Medicine|February 27, 2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. ReplyScott Kopetz, Axel Grothey, Josep Tabernero
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 15, 2012
Depicting the evolving scenario of translational-guided drug developmentG Argilés, J Rodon, J Tabernero
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Drug development in the era of personalized oncology: from population-based trials to enrichment and prescreening strategiesRodrigo Dienstmann, Jordi Rodon, Josep Tabernero
Cell Cycle (Georgetown, Tex.)|December 9, 2014
Multi-target angiokinase inhibitors to fight resistanceOriol Casanovas, Ramon Salazar, Josep Tabernero
Current Treatment Options in Oncology|September 17, 2015
First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405Elena Elez, Guillem Argilés, Josep Tabernero
European Journal of Investigation in Health, Psychology and Education|September 20, 2021
Development and Validation of the Social Network Addiction Scale (SNAddS-6S)Esther Cuadrado, Rocío Rojas, Carmen Tabernero
Future Oncology (London, England)|November 13, 2025
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line <i>BRAF</i> V600E-mutant metastatic colorectal cancerScott Kopetz, Josep Tabernero, Elena Élez
Pageof 175